For #SLE pleuropericarditis: recommendation intentionally tries to leverage use of colchicine/NSAIDs vs. GCs But there are special situations where GCs are req’d: > Concomitant active SLE > CI to NSAIDs/Col > Recurrent pericarditis > Late pregnancy > 💊interxns #ACR25 @RheumNow https://t.co/sLL72t3Qhf

HIGH YIELD🚨Summary of Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ysSTKOz1ym

Year in Review: Regency Trial showed that LN pts given obinutuzumab achieved CRR at 76 wks (46.4%) vs. PBO. Take note: the Regency trial did not evaluate the extrarenal effects of Obinutuzumab in #SLE, thats for a diff study. #ACR25 @RheumNow https://t.co/WJssU1DbzZ

#ACR25 New ACR Non-Renal #SLE lifecourse Guideline. 3 strong recommendations: - HCQ routinely unless contraindicated - Taper GC to =< 5mg/d - Escalate therapy in any organ system if refractory to initial therapy *Organ-specific: Conditional recommendations only @RheumNow https://t.co/w9rfcvwGHy

Don’t fight #AI #RCTs - #AI better at soft Skills alone Vs #Medical input and AI as we tend to Disbelieve the model & mess it up! #LLM can accurately take a #history Bottom line EMBRACE AI ?check it too #ACR25 @RheumNow @ACRheum #artificial #intelligence and #medicine 26217 https://t.co/22MYD4QqzH

@ACRheum SLE Treatment Guidelines 2025 Key points: - HCQ is standard - steroids with precision - immunosuppressive therapies early - shared decision making #ACR25 @RheumNow https://t.co/AYIXE6dLlW

Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z

Wondering whether rheumatology is the specialty for you? Dr Bryant England kicks off the clinical science #YearInReview with an impressive overview of what a year in rheumatology looks like. New drugs, new devices, new disease names! 🤯 #ChooseRheumatology #ACR25 @RheumNow https://t.co/uLrNFPgeAn

#Sjogren disease is here to stay. “The name has caught up to the science of SD and this can translate to better treatment outcomes for patients” - Dr. Bryant England #ACR25 @RheumNow https://t.co/M4r0XXkswv

Basic Sci Year in Review: Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & IL-17 pathways. I3S induces epidermal thickening in mice and correlated with dse activity in patients with #psoriasis #ACR25 @RheumNow https://t.co/WNNbBBESQ3

Rheum guidelines balance data & context. Beyond evidence, factors like cost, equity & feasibility shape recs. GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$ @RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4

12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/kZMQ0UsimB

From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX